SYK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
SYK is a solid long-term quality stock, but based on the current setup it is not a clear buy right now for a beginner investor who wants long-term exposure and does not want to wait for an ideal entry. The stock is trading below its pivot with mixed momentum, recent analyst targets have been cut broadly after a weak Q1 disrupted by cybersecurity issues, and hedge funds have been selling. I would not call this a strong buy at the current price; hold and wait for either a better entry near support or evidence that the post-cyber disruption rebound is clearly improving.
Current price is 305.97, below the pivot at 311.15 and close to first support at 301.83. RSI_6 at 45.57 is neutral, showing no strong oversold signal. MACD histogram is positive at 2.075 but contracting, which suggests momentum is still weakening rather than accelerating. Moving averages are converging, pointing to a sideways-to-slightly cautious trend rather than a strong uptrend. Short-term trend signals are mixed, with next-day and next-week estimates modestly positive but the next-month estimate slightly negative.
Stryker launched the Pangea Plating System in Europe, which is a positive product and growth catalyst. Analysts also noted that the company expects to recover much of the revenue lost from the Q1 cyber disruption later in the year, and several firms pointed to healthy procedure growth, hospital capital spending, and new product launches as supportive long-term drivers. Bernstein and BTIG specifically highlighted visibility into revenue recovery and underlying healthy trends.
Q1 results were hurt by a cybersecurity incident that delayed procedures and capital order fulfillment, causing organic growth to fall well below expectations. Several analysts cut price targets meaningfully after the quarter, including Truist, Barclays, Deutsche Bank, and others. Hedge funds have been selling aggressively, up 119.77% over the last quarter. The stock is also trading under its pivot, showing short-term technical weakness.
Latest quarter: Q1 FY2026. The quarter was mixed to weak because the cyber incident materially disrupted operations and pushed organic growth down to 2.4%, far below the earlier expected pace. Analysts said the company likely has visibility to recover a large portion of the lost revenue later in the year, but the latest quarter itself was clearly below Street expectations and showed slower growth versus prior periods.
Recent analyst sentiment is mixed but mostly cautious. The trend is a wave of price target cuts after Q1, with Truist lowering to $330 and downgrading to Hold, Barclays cutting to $394 while keeping Overweight, Goldman nudging target to $361 with Neutral, Bernstein to $410 with Outperform, JPMorgan to $400, Baird to $385, Deutsche Bank to $315 with Hold, Needham to $418 with Buy, and BTIG to $379 with Buy. The Wall Street pros view is that the long-term business remains strong, but near-term execution was hurt by the cyber disruption and multiple compression is limiting valuation upside. No recent politician or congress trading data is available.
